Mizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 94.7%

Neg 94.7% Neu 0% Pos 0%

Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $6 to $4.